CUTAIA, ORNELLA
 Distribuzione geografica
Continente #
NA - Nord America 1.014
EU - Europa 794
AS - Asia 102
AF - Africa 5
SA - Sud America 1
Totale 1.916
Nazione #
US - Stati Uniti d'America 1.013
IE - Irlanda 226
IT - Italia 161
GB - Regno Unito 137
RU - Federazione Russa 62
CN - Cina 60
SE - Svezia 59
UA - Ucraina 38
FR - Francia 33
DE - Germania 26
ES - Italia 18
SG - Singapore 18
FI - Finlandia 16
VN - Vietnam 12
PL - Polonia 4
BE - Belgio 3
CH - Svizzera 3
IN - India 3
ZA - Sudafrica 3
HR - Croazia 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
BD - Bangladesh 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GR - Grecia 1
HK - Hong Kong 1
IL - Israele 1
KG - Kirghizistan 1
LK - Sri Lanka 1
MA - Marocco 1
MY - Malesia 1
PA - Panama 1
PH - Filippine 1
PT - Portogallo 1
Totale 1.916
Città #
Dublin 225
Fairfield 199
Southend 123
Woodbridge 92
Ashburn 84
Cambridge 84
Seattle 72
Wilmington 64
Houston 61
Siena 44
Chandler 36
Jacksonville 36
New York 36
Ann Arbor 30
Princeton 30
Shanghai 23
San Diego 18
Beijing 17
Málaga 17
San Mateo 14
Helsinki 13
Dong Ket 11
Singapore 11
Palermo 9
Dearborn 6
Fremont 6
Labico 5
Nanjing 5
San Giovanni Valdarno 5
Boardman 4
Hounslow 4
Milan 4
Montevarchi 4
Moscow 4
Redwood City 4
Santa Clara 4
Venezia 4
Asciano 3
Brussels 3
Chiswick 3
Empoli 3
Florence 3
Lavis 3
London 3
Rome 3
Zurich 3
Altamura 2
Bratislava 2
Chiusdino 2
Düsseldorf 2
Johannesburg 2
Novara 2
Pistoia 2
Sesto Fiorentino 2
Torino 2
Trieste 2
Warsaw 2
Zagreb 2
Abidjan 1
Arezzo 1
Athens 1
Bishkek 1
Brno 1
Centurion 1
Changsha 1
Chicago 1
Colombo 1
Dhaka 1
Ferentino 1
Figline Valdarno 1
Guangzhou 1
Guiyang 1
Haikou 1
Hefei 1
Hong Kong 1
Jiaxing 1
Jinan 1
Kilburn 1
La Paz 1
Lanzhou 1
Lappeenranta 1
Lisbon 1
Madrid 1
Menderes 1
Naples 1
Newark 1
Ningbo 1
Phoenix 1
Piscataway 1
Reggio Calabria 1
Roseto Degli Abruzzi 1
San Francisco 1
Scarperia 1
Stagno 1
Tallinn 1
Tel Aviv 1
Wandsworth 1
Zhengzhou 1
Totale 1.499
Nome #
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 212
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 179
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 155
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 143
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 129
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 126
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 120
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 116
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 111
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 103
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 99
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 84
ICOS expression as immunologic marker in immune activating monoclonal antibodies 74
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 65
null 58
“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 58
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 57
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 36
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 30
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 28
Totale 1.983
Categoria #
all - tutte 7.582
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.582


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020515 0 0 6 65 57 43 76 82 74 45 21 46
2020/2021395 15 47 39 42 22 42 20 56 17 45 15 35
2021/2022236 11 43 20 6 9 11 13 9 6 25 39 44
2022/2023269 21 16 44 21 8 48 11 18 27 18 25 12
2023/2024373 17 9 38 17 12 110 128 6 5 5 16 10
2024/2025103 20 20 63 0 0 0 0 0 0 0 0 0
Totale 1.983